BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11855748)

  • 1. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.
    Fyfe D; Raynaud F; Langley RE; Newell DR; Halbert G; Gardner C; Clayton K; Woll PJ; Judson I; Carmichael J
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):1-6. PubMed ID: 11855748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
    Fyfe D; Price C; Langley RE; Pagonis C; Houghton J; Osborne L; Woll PJ; Gardner C; Baguley BC; Carmichael J;
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):333-7. PubMed ID: 11345650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
    Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
    Hardy JR; Harvey VJ; Paxton JW; Evans P; Smith S; Grove W; Grillo-Lopez AJ; Baguley BC
    Cancer Res; 1988 Nov; 48(22):6593-6. PubMed ID: 3180070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
    Heath EI; Bible K; Martell RE; Adelman DC; Lorusso PM
    Invest New Drugs; 2008 Feb; 26(1):59-65. PubMed ID: 17938863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
    Panasci L; Stinson SF; Melnychuk D; Sandor V; Miller WH; Batist G; Patenaude F; Bangash N; Panarello L; Alaoui-Jamali M; Sausville E
    J Clin Oncol; 2003 Jan; 21(2):232-40. PubMed ID: 12525514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
    Ratliff AF; Wilson J; Hum M; Marling-Cason M; Rose K; Winick N; Kamen BA
    J Clin Oncol; 1998 Apr; 16(4):1458-64. PubMed ID: 9552052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
    Rowinsky EK; Grochow LB; Hantel A; Ettinger DS; Vito BL; Donehower RC
    Invest New Drugs; 1989 Nov; 7(4):317-25. PubMed ID: 2599802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
    Pagani O; Zucchetti M; Sessa C; de Jong J; D'Incalci M; De Fusco M; Kaeser-Fröhlich A; Hanauske A; Cavalli F
    Cancer Chemother Pharmacol; 1996; 38(6):541-7. PubMed ID: 8823496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.